Abstract
The efficacy and tolerance of parenterally administered piperacillin were evaluated in 50 adult patients hospitalized with systemic and urinary tract infections. Dosage for 46 patients was 4 to 12 g daily and for 4 patients, 16 to 24 g daily; in each case divided doses were given every 4 to 6 h. The duration of treatment for most patients was 5 to 10 days. Of the 50 patients, 45 (90%) were considered cured, and 57 (89%) of the 64 pathogens isolated were eradicated by piperacillin treatment. Side effects, reported by 12 patients, were mild to moderate in degree and consisted of vein irritation, thrombophlebitis, pain at the injection site, and diarrhea, Piperacillin appears to be a highly effective antibiotic for treating infections caused by susceptible gram-positive and gram-negative microorganisms.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dickinson G. M., Cleary T. J., Hoffman T. A. Comparative evaluation of piperacillin in vitro. Antimicrob Agents Chemother. 1978 Dec;14(6):919–921. doi: 10.1128/aac.14.6.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fu K. P., Neu H. C. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother. 1978 Mar;13(3):358–367. doi: 10.1128/aac.13.3.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
- George W. L., Lewis R. P., Meyer R. D. Susceptibility of cephalothin-resistant gram-negative bacilli to piperacillin, cefuroxime, and other selected antibiotics. Antimicrob Agents Chemother. 1978 Mar;13(3):484–489. doi: 10.1128/aac.13.3.484. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gootz T. D., Sanders C. C., Sanders W. E., Jr In vitro activity of furazlocillin (Bay k 4999) compared with those of mezlocillin, piperacillin, and standard beta-lactam antibiotics. Antimicrob Agents Chemother. 1979 Jun;15(6):783–791. doi: 10.1128/aac.15.6.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N., Packer R. R., Barry A. L., Badal R. E., Thornsberry C., Baker C. Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicin. J Antibiot (Tokyo) 1979 Jan;32(1):29–35. doi: 10.7164/antibiotics.32.29. [DOI] [PubMed] [Google Scholar]
- Kuck N. A., Redin G. S. In vitro and in vivo activity of piperacillin, a new broad-spectrum semisynthetic penicillin. J Antibiot (Tokyo) 1978 Nov;31(11):1175–1182. doi: 10.7164/antibiotics.31.1175. [DOI] [PubMed] [Google Scholar]
- Monif G. R., Clark P. R., Shuster J. J., Baer H. Susceptibility of the anaerobic bacteria, group D streptococci, Enterobacteriaceae, and Pseudomonas to semisynthetic penicillins: carbenicillin, piperacillin, and ticarcillin. Antimicrob Agents Chemother. 1978 Nov;14(5):643–649. doi: 10.1128/aac.14.5.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Verbist L. In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity. Antimicrob Agents Chemother. 1978 Mar;13(3):349–357. doi: 10.1128/aac.13.3.349. [DOI] [PMC free article] [PubMed] [Google Scholar]